menu

Overcoming Barriers to Timely Diagnosis and Classification of Interstitial Lung Disease: Considerations for Radiologists

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Overcoming Barriers to Timely Diagnosis and Classification of Interstitial Lung Disease: Considerations for Radiologists

1.00 credits
60 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Learn about making timely and accurate diagnoses of ILD, review radiologic patterns, and discuss the importance of multidisciplinary care in radiology.

  • Disclosure of Conflicts of Interest

    Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    David A. Lynch, MB, BChconsultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, Calyx, Daiichi Sankyo.

    The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

  • Target Audience

    This educational initiative is intended for community- and academic-based radiologists and other healthcare providers who care for patients with or at risk for Interstitial Lung Disease (ILD). 

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Identify clinical and imaging patterns used in the diagnosis and classification of interstitial lung disease (ILD)
    • Integrate current guideline-based HRCT patterns necessary for the diagnosis of idiopathic pulmonary fibrosis (IPF)
    • Discuss how multidisciplinary discussion (MDD) improves accuracy and confidence in making the diagnosis and classification of ILD
    • Construct a follow-up and referral plan for identified interstitial lung abnormalities (ILA) in the context of patient-specific characteristics
  • Accreditation and Credit Designation Statements

    In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education
    CCO designates this enduring material for a maximum of  1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by Clinical Care Options, LLC.

  • Commercial Support

    This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

  • Goal Statement

    The goal of this activity is to improve the knowledge and competence of radiologists in timely in accurate diagnosis of ILD including identification, referral, and follow-up of ILA, as well as radiologic patterns consistent with fibrosis ILDs and importance of MDD in the diagnosis and classification of ILD.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Learn about making timely and accurate diagnoses of ILD, review radiologic patterns, and discuss the importance of multidisciplinary care in radiology.

  • Disclosure of Conflicts of Interest

    Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    David A. Lynch, MB, BChconsultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, Calyx, Daiichi Sankyo.

    The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

  • Target Audience

    This educational initiative is intended for community- and academic-based radiologists and other healthcare providers who care for patients with or at risk for Interstitial Lung Disease (ILD). 

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Identify clinical and imaging patterns used in the diagnosis and classification of interstitial lung disease (ILD)
    • Integrate current guideline-based HRCT patterns necessary for the diagnosis of idiopathic pulmonary fibrosis (IPF)
    • Discuss how multidisciplinary discussion (MDD) improves accuracy and confidence in making the diagnosis and classification of ILD
    • Construct a follow-up and referral plan for identified interstitial lung abnormalities (ILA) in the context of patient-specific characteristics
  • Accreditation and Credit Designation Statements

    In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education
    CCO designates this enduring material for a maximum of  1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by Clinical Care Options, LLC.

  • Commercial Support

    This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

  • Goal Statement

    The goal of this activity is to improve the knowledge and competence of radiologists in timely in accurate diagnosis of ILD including identification, referral, and follow-up of ILA, as well as radiologic patterns consistent with fibrosis ILDs and importance of MDD in the diagnosis and classification of ILD.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule22 May 2024